全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Identification of Four Novel Synonymous Substitutions in the X-Linked Genes Neuroligin 3 and Neuroligin 4X in Japanese Patients with Autistic Spectrum Disorder

DOI: 10.1155/2012/724072

Full-Text   Cite this paper   Add to My Lib

Abstract:

Mutations in the X-linked genes neuroligin 3 (NLGN3) and neuroligin 4X (NLGN4X) were first implicated in the pathogenesis of X-linked autism in Swedish families. However, reports of mutations in these genes in autism spectrum disorder (ASD) patients from various ethnic backgrounds present conflicting results regarding the etiology of ASD, possibly because of genetic heterogeneity and/or differences in their ethnic background. Additional mutation screening study on another ethnic background could help to clarify the relevance of the genes to ASD. We scanned the entire coding regions of NLGN3 and NLGN4X in 62 Japanese patients with ASD by polymerase chain reaction-high-resolution melting curve and direct sequencing analyses. Four synonymous substitutions, one in NLGN3 and three in NLGN4X, were identified in four of the 62 patients. These substitutions were not present in 278 control X-chromosomes from unrelated Japanese individuals and were not registered in the database of Single Nucleotide Polymorphisms build 132 or in the Japanese Single Nucleotide Polymorphisms database, indicating that they were novel and specific to ASD. Though further analysis is necessary to determine the physiological and clinical importance of such substitutions, the possibility of the relevance of both synonymous and nonsynonymous substitutions with the etiology of ASD should be considered. Introduction Neuroligin 3 (NLGN3) and Neuroligin 4X (NLGN4X) are members of neuroligins expressed in the postsynaptic neurons and mediate transsynaptic signaling by interacting their ligand, neurexins [1]. Mutations in the X-linked genes NLGN3 and NLGN4X (GenBank accession numbers NM_181303.1 and NM_020742.2, resp.) were first reported as being involved in X-linked autistic spectrum disorder (ASD; MIM#300425?and MIM#300495) in Swedish families [2]. Some reports have also indicated that NLGN3 and NLGN4X are responsible for ASD. Mutations in these genes including 5?missense mutations [2–5], two small in-del mutations, which lead to a premature stop codon in the transcript [2, 6], an exon skipping mutation [7], and a large deletion [8], have been identified in ASD patients (Table 1). In vitro experiments using NLGN3 and NLGN4X proteins carrying amino acid changes that were identified in ASD patients indicated that the gene mutations could cause ASD by a loss-of-function mechanism [5, 9]. Neuroligin 3?? p.R451C knock-in mice and neuroligin 4X-deficient mice exhibited autism-related behaviors [10, 11]. In addition, recent mutation screening studies revealed that the p.K378R substitution in the

References

[1]  T. C. Südhof, “Neuroligins and neurexins link synaptic function to cognitive disease,” Nature, vol. 455, no. 7215, pp. 903–911, 2008.
[2]  S. Jamain, H. Quach, C. Betancur et al., “Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism,” Nature Genetics, vol. 34, no. 1, pp. 27–29, 2003.
[3]  J. Yan, G. Oliveira, A. Coutinho et al., “Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients,” Molecular Psychiatry, vol. 10, no. 4, pp. 329–332, 2005.
[4]  A. Pampanos, K. Volaki, E. Kanavakis et al., “A substitution involving the NLGN4 gene associated with autistic behavior in the Greek population,” Genetic testing and molecular biomarkers, vol. 13, no. 5, pp. 611–615, 2009.
[5]  C. Zhang, J. M. Milunsky, S. Newton et al., “A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export,” Journal of Neuroscience, vol. 29, no. 35, pp. 10843–10854, 2009.
[6]  F. Laumonnier, F. Bonnet-Brilhault, M. Gomot et al., “X-Linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family,” American Journal of Human Genetics, vol. 74, no. 3, pp. 552–557, 2004.
[7]  Z. Talebizadeh, D. Y. Lam, M. F. Theodoro, D. C. Bittel, G. H. Lushington, and M. G. Butler, “Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism,” Journal of medical genetics, vol. 43, no. 5, p. e21, 2006.
[8]  A. Lawson-Yuen, J. S. Saldivar, S. Sommer, and J. Picker, “Familial deletion within NLGN4 associated with autism and Tourette syndrome,” European Journal of Human Genetics, vol. 16, no. 5, pp. 614–618, 2008.
[9]  B. Chih, S. K. Afridi, L. Clark, and P. Scheiffele, “Disorder-associated mutations lead to functional inactivation of neuroligins,” Human Molecular Genetics, vol. 13, no. 14, pp. 1471–1477, 2004.
[10]  K. Tabuchi, J. Blundell, M. R. Etherton et al., “A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice,” Science, vol. 318, no. 5847, pp. 71–76, 2007.
[11]  S. Jamain, K. Radyushkin, K. Hammerschmidt et al., “Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1710–1715, 2008.
[12]  J. Yu, X. He, D. Yao, Z. Li, H. Li, and Z. Zhao, “A sex-specific association of common variants of neuroligin genes (NLGN3 and NLGN4X) with autism spectrum disorders in a Chinese Han cohort,” Behavioral and Brain Functions, vol. 7, p. 13, 2011.
[13]  T. Ylisaukko-oja, K. Rehnstr?m, M. Auranen et al., “Analysis of four neuroligin genes as candidates for autism,” European Journal of Human Genetics, vol. 13, no. 12, pp. 1285–1292, 2005.
[14]  A. K. Wermter, I. Kamp-Becker, K. Strauch, G. Schulte-K?rne, and H. Remschmidt, “No evidence for involvement of genetic variants in the x-linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level,” American Journal of Medical Genetics B, vol. 147, no. 4, pp. 535–537, 2008.
[15]  J. B. Vincent, D. Kolozsvari, W. S. Roberts, P. F. Bolton, H. M. D. Gurling, and S. W. Scherer, “Mutation screening of X-chromosomal neuroligin genes: No mutations in 196 autism probands,” American Journal of Medical Genetics, vol. 129, no. 1, pp. 82–84, 2004.
[16]  J. Gauthier, A. Bonnel, J. St-Onge et al., “NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population,” American Journal of Medical Genetics, vol. 132, no. 1, pp. 74–75, 2005.
[17]  F. Blasi, E. Bacchelli, G. Pesaresi, S. Carone, A. J. Bailey, and E. Maestrini, “Absence of coding mutations in the X-linked genes neuroligin 3 and neuroligin 4 in individuals with autism from the IMGSAC collection,” American Journal of Medical Genetics, vol. 141, no. 3, pp. 220–221, 2006.
[18]  T. Marui, O. Hashimoto, E. Nanba et al., “Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population,” American Journal of Medical Genetics, vol. 131, no. 1, pp. 43–47, 2004.
[19]  K. M. Ririe, R. P. Rasmussen, and C. T. Wittwer, “Product differentiation by analysis of DNA melting curves during the polymerase chain reaction,” Analytical Biochemistry, vol. 245, no. 2, pp. 154–160, 1997.
[20]  A. D. Laurie, M. P. Smith, and P. M. George, “Detection of factor VIII gene mutations by high-resolution melting analysis,” Clinical Chemistry, vol. 53, no. 12, pp. 2211–2214, 2007.
[21]  P. Awadalla, J. Gauthier, R. A. Myers et al., “Direct measure of the de novo mutation rate in autism and schizophrenia cohorts,” American Journal of Human Genetics, vol. 87, no. 3, pp. 316–324, 2010.
[22]  L. Sie, S. Loong, and E. K. Tan, “Utility of lymphoblastoid cell lines,” Journal of Neuroscience Research, vol. 87, no. 9, pp. 1953–1959, 2009.
[23]  C. Kimchi-Sarfaty, J. M. Oh, I. W. Kim et al., “A “silent” polymorphism in the MDR1 gene changes substrate specificity,” Science, vol. 315, no. 5811, pp. 525–528, 2007.
[24]  Z. E. Sauna, C. Kimchi-Sarfaty, S. V. Ambudkar, and M. M. Gottesman, “The sounds of silence: synonymous mutations affect functions,” Pharmacogenomics, vol. 8, no. 6, pp. 527–532, 2007.
[25]  K. E. Knobe, E. Sj?rin, and R. C. R. Ljung, “Why does the mutation G17736A/Val107Val (silent) in the F9 gene cause mild haemophilia B in five Swedish families?” Haemophilia, vol. 14, no. 4, pp. 723–728, 2008.
[26]  J. M. Schwarz, C. R?delsperger, M. Schuelke, and D. Seelow, “MutationTaster evaluates disease-causing potential of sequence alterations,” Nature Methods, vol. 7, no. 8, pp. 575–576, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133